Claims
- 1. An implantable catheter filled with a locking composition comprising:
at least one lower alcohol in a range from 1% to 99% by volume; and at least one other anti-microbial or anti-coagulant compound in a range from 1% to 99% by volume.
- 2. An implanted catheter as in claim 1, wherein the lower alcohol is selected from the group consisting of ethanol, propanol, and butanol.
- 3. An implanted catheter as in claim 2, wherein the lower alcohol is isopropanol.
- 4. An implanted catheter as in claim 1, wherein the at least one other anti-microbial compound is selected from the group consisting of taurolidine and triclosan.
- 5. An implanted catheter as in claim 1, wherein the at least one anti-coagulant compound is selected from the group consisting of riboflavin, sodium citrate, ethylene diamine tetraacetic acid, and citric acid.
- 6. An implanted catheter as in claim 5, wherein the at least one anti-coagulant compound is riboflavin at about 4% by volume.
- 7. An implanted catheter as in claim 5, wherein the at least one anti-coagulant compound is sodium citrate at about 4% by volume.
- 8. An implanted catheter as in claim 5, wherein the at least one anti-coagulant compound is ethylene diamine tetraacetic acid at about 4% by volume.
- 9. An implanted catheter as in claim 5, wherein the at least one anti-coagulant compound is citric acid at about 4% by volume.
- 10. A locking composition comprising:
at least one lower alcohol in a range from 1% to 99% by volume; and at least one other anti-microbial or anti-coagulant compound in a range from 1% to 99% by volume.
- 11. A composition as in claim 10, wherein the lower alcohol is selected from the group consisting of ethanol, propanol, and butanol.
- 12. A composition as in claim 11, wherein the lower alcohol is isopropanol.
- 13. A composition as in claim 10, wherein the at least one other anti-microbial compound is selected from the group consisting of taurolidine and triclosan.
- 14. A composition as in claim 10, wherein the at least one anti-coagulant compound is selected from the group consisting of riboflavin, sodium citrate, ethylene diamine tetraacetic acid, and citric acid.
- 15. A composition as in claim 14, wherein the at least one anti-coagulant compound is riboflavin at about 4% by volume.
- 16. A composition as in claim 14, wherein the at least one anti-coagulant compound is sodium citrate at about 4% by volume.
- 17. A composition as in claim 14, wherein the at least one anti-coagulant compound is ethylene diamine tetraacetic acid at about 4% by volume.
- 18. A composition as in claim 14, wherein the at least one anti-coagulant compound is citric acid at about 4% by volume.
- 19. A method for disinfecting an implanted catheter, said method comprising:
introducing an anti-microbial solution to a lumen of the catheter, wherein at least a portion of the catheter permits sufficient diffusion of the anti-microbial solution outwardly from the lumen into tissue surrounding the catheter to eradicate an existing infection, the anti-microbial solution comprising at least one lower alcohol.
- 20. A method as in claim 19, wherein the lower alcohol is selected from the group consisting of ethanol, propanol, and butanol.
- 21. A method as in claim 20, wherein the lower alcohol is isopropanol.
- 22. A method as in claim 19, wherein the anti-microbial solution further comprises at least one other anti-microbial or anti-coagulant compound.
- 23. A method as in claim 22, wherein the other anti-microbial compound is selected from the group consisting of taurolidine and triclosan.
- 24. A method as in claim 22, wherein the at least one anti-coagulant compound is selected from the group consisting of riboflavin, sodium citrate, ethylene diamine tetraacetic acid, and citric acid.
- 25. A kit for disinfecting an implantable catheter, said kit comprising:
a container holding a volume of a solution comprising a lower alcohol; and instructions for use setting forth a method comprising introducing the solution to a lumen of the catheter, wherein at least a portion of the catheter permits sufficient diffusion of the solution outwardly from the lumen into tissue surrounding the catheter to eradicate an existing infection.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of, and claims the benefit of priority from, U.S. patent application Ser. No. 09/611,421, filed Jul. 7, 2000, which was a continuation-in-part of U.S. patent application Ser. No. 09/359,842, filed Jul. 23, 1999, the full disclosures of which are incorporated herein by reference.
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09611421 |
Jul 2000 |
US |
Child |
09859886 |
May 2001 |
US |
Parent |
09359842 |
Jul 1999 |
US |
Child |
09611421 |
Jul 2000 |
US |